Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2011 | 12-2010 | 09-2010 | 06-2010 | 03-2010 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 863,818 | 4,626,172 | 3,185,325 | 2,294,665 | 1,003,015 |
| Depreciation Amortization | 745,667 | 2,624,305 | 1,914,727 | 1,237,703 | 562,501 |
| Accounts receivable | 298,953 | -394,665 | 476,209 | 245,835 | 291,638 |
| Other Working Capital | 343,737 | 658,784 | 423,325 | 220,004 | 242,007 |
| Other Operating Activity | -241,029 | 1,221,385 | 419,876 | -127,158 | -576,409 |
| Operating Cash Flow | $2,011,146 | $8,735,981 | $6,419,462 | $3,871,049 | $1,522,752 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -391,813 | -1,015,075 | -723,742 | -518,657 | -245,143 |
| Net Acquisitions | N/A | -9,433,243 | -9,120,043 | -6,920,043 | -6,415,648 |
| Purchase Of Investment | N/A | -805,932 | N/A | N/A | N/A |
| Sale Of Investment | -1,917,221 | 954,361 | 1,973,697 | 1,959,380 | 874,139 |
| Other Investing Activity | 7,804 | -1,888,431 | -1,877,838 | -1,875,608 | -1,872,108 |
| Investing Cash Flow | $-2,301,230 | $-12,188,320 | $-9,747,926 | $-7,354,928 | $-7,658,760 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 396,213 | -203,854 | -1,419,671 | -1,345,857 | 775,006 |
| Debt Issued | N/A | 4,000,000 | 3,000,000 | 3,000,000 | N/A |
| Debt Repayment | -500,582 | -1,673,998 | -1,254 | -1,254 | -1,254 |
| Common Stock Issued | 175,752 | 328,411 | 272,045 | 203,588 | 188,169 |
| Common Stock Repurchased | -71,750 | -866,825 | -866,173 | -863,847 | -861,368 |
| Dividend Paid | -683,967 | -2,671,475 | -1,979,374 | -1,299,951 | -620,752 |
| Financing Cash Flow | $-684,334 | $-1,087,741 | $-994,427 | $-307,321 | $-520,199 |
| Exchange Rate Effect | 66,203 | -620,893 | -668,303 | -696,437 | -586,312 |
| Beginning Cash Position | 3,648,371 | 8,809,339 | 8,809,339 | 8,809,339 | 8,809,339 |
| End Cash Position | 2,740,156 | 3,648,371 | 3,818,145 | 4,321,702 | 1,566,820 |
| Net Cash Flow | $-908,215 | $-5,160,968 | $-4,991,194 | $-4,487,637 | $-7,242,519 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,011,146 | 8,735,981 | 6,419,462 | 3,871,049 | 1,522,752 |
| Capital Expenditure | -391,813 | -1,015,075 | -723,742 | -518,657 | -245,143 |
| Free Cash Flow | 1,619,333 | 7,720,906 | 5,695,720 | 3,352,392 | 1,277,609 |